Vladimir Chulanov, MD, PhD

Sechenov University
Moscow, Moskva, Russia

Disclosure(s): AbbVie: Advisor/Consultant, Expert Testimony; AstraZeneca: Advisor/Consultant, Expert Testimony; Bristol Myers Squibb: Advisor/Consultant, Expert Testimony; Gilead Sciences, Inc.: Advisor/Consultant, Expert Testimony; GSK: Advisor/Consultant, Expert Testimony; Hepatera: Advisor/Consultant, Expert Testimony; Merck Sharp & Dohme: Advisor/Consultant, Expert Testimony; Roche: Advisor/Consultant, Expert Testimony; R-Pharm: Advisor/Consultant, Expert Testimony

Presentation(s):

• 83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

  Thursday, October 17, 2024
  10:45 AM – 11:00 AM US PT

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT